Alyson Prom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alyson Prom has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Alexander H. Toledo
University of North Carolina at Chapel Hill, USA
1 shared publication - Anita Yang
University of North Carolina Health Care, Chapel Hill, North Carolina, USA
1 shared publication - Carolyn Coulter
Department of Pharmacy University of North Carolina Medical Center Chapel Hill North Carolina USA
1 shared publication - Christina Teeter Doligalski
Department of Pharmacy UNC Health Chapel Hill North Carolina USA
1 shared publication - Elizabeth S. Kotzen
Division of Nephrology and Hypertension University of North Carolina Medical Center Chapel Hill North Carolina USA
1 shared publication - Eric T. Weimer
Department of Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
1 shared publication
Latest Publications
- 2 February 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (2)
Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen
Introduction: In kidney transplant recipients (KTRs), steroid‐free maintenance regimens are used to minimize the negative impact of steroid use. Studies comparing alemtuzumab (ALZ) and anti‐thymocyte globulin (ATG) with rapid steroid withdrawal are limited. The aim of this study was to assess a composite outcome of incidence of de novo donor specific antibodies (dnDSAs), biopsy proven rejection (BPAR), graft failure, or death in KTRs receiving ALZ or ATG with a steroid‐free maintenance regimen.Methods: A single‐center, retrospective cohort study was conducted in adult KTRs who underwent rapid steroid withdrawal. There were two cohorts, KTRs who received induction with ALZ compared to ATG. The primary composite outcome was incidence of dnDSAs, BPAR, graft failure, or death. Secondary outcomes included renal function, cytomegalovirus (CMV) and BK viremia, and leukopenia.Results: Two hundred twenty‐five KTRs were included where 146 received ALZ and 79 received ATG. The Cox proportional hazard of the primary composite outcome in the ALZ compared to ATG group was not significant (unadjusted model HR 1.37, 95% CI .74–2.55). Individual incidences of composite outcome were similar. There was a difference in estimated glomerular filtration rate at 12 months post‐transplant (55.7 vs. 62.3 mL/min/1.73m2, p = .03) and leukopenia at 3 months (3.7 vs. 4.2 × 109/L, p = .03). Other secondary outcomes were similar.Conclusions: There was no difference in composite outcome for dnDSAs, BPAR, graft failure, and death.
- 2 February 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (2)
Alemtuzumab versus anti‐thymocyte globulin in kidney transplant recipients receiving a rapid steroid withdrawal regimen
Introduction: In kidney transplant recipients (KTRs), steroid‐free maintenance regimens are used to minimize the negative impact of steroid use. Studies comparing alemtuzumab (ALZ) and anti‐thymocyte globulin (ATG) with rapid steroid withdrawal are limited. The aim of this study was to assess a composite outcome of incidence of de novo donor specific antibodies (dnDSAs), biopsy proven rejection (BPAR), graft failure, or death in KTRs receiving ALZ or ATG with a steroid‐free maintenance regimen.Methods: A single‐center, retrospective cohort study was conducted in adult KTRs who underwent rapid steroid withdrawal. There were two cohorts, KTRs who received induction with ALZ compared to ATG. The primary composite outcome was incidence of dnDSAs, BPAR, graft failure, or death. Secondary outcomes included renal function, cytomegalovirus (CMV) and BK viremia, and leukopenia.Results: Two hundred twenty‐five KTRs were included where 146 received ALZ and 79 received ATG. The Cox proportional hazard of the primary composite outcome in the ALZ compared to ATG group was not significant (unadjusted model HR 1.37, 95% CI .74–2.55). Individual incidences of composite outcome were similar. There was a difference in estimated glomerular filtration rate at 12 months post‐transplant (55.7 vs. 62.3 mL/min/1.73m2, p = .03) and leukopenia at 3 months (3.7 vs. 4.2 × 109/L, p = .03). Other secondary outcomes were similar.Conclusions: There was no difference in composite outcome for dnDSAs, BPAR, graft failure, and death.
- 4 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (6) , 570-575
Pharmacist‐led dosing reduces tacrolimus intrapatient variability in lung transplant recipients
- 4 May 2023
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 6 (6) , 570-575
Pharmacist‐led dosing reduces tacrolimus intrapatient variability in lung transplant recipients